Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Sep;27(9):1467-1476.
doi: 10.1007/s10147-022-02204-x. Epub 2022 Jun 29.

A clinical investigation of recurrence and lost follow-up after renal cell carcinoma surgery: a single-center, long-term, large cohort, retrospective study

Takayuki Arai  1 , Tomokazu Sazuka  2 , Hiroaki Sato  1 , Mayuko Kato  1 , Shuhei Kamada  1 , Sota Katsura  1 , Ayako Seito  1 , Shu Miyamoto  1 , Ken Wakai  1 , Nobuyoshi Takeuchi  1 , Yusuke Imamura  1 , Shinichi Sakamoto  1 , Akira Komiya  1 , Tomohiko Ichikawa  1
Affiliations
Review

A clinical investigation of recurrence and lost follow-up after renal cell carcinoma surgery: a single-center, long-term, large cohort, retrospective study

Takayuki Arai et al. Int J Clin Oncol. 2022 Sep.

Abstract

Background: Late recurrence of renal cell carcinoma (RCC) is observed in some postoperative patients. In addition, some of these patients are lost to long-term postoperative follow-up. We reviewed the treatment results and prognosis of postoperative patients with RCC at Chiba University Hospital, with the aim of clarifying the proportion and background of patients lost to follow-up.

Methods: This retrospective study included 1176 RCC patients who underwent radical or/and partial nephrectomy. Overall survival (OS), cancer-specific survival (CSS), recurrence-free survival (RFS), and lost follow-up free survival (LFFS) were evaluated and the risk factors for LFFS identified.

Results: The median RFS for stage II and II cases was 188.3 and 104.0 months, respectively. Even in stage I, recurrence was observed in about 20% of patients 20 years after surgery. The Kaplan-Meier curve for LFFS showed a linear descent over time, with 50% of patients lost to follow-up within 25 years. Older age (≥ 62 years), histological type (clear cell RCC), and no recurrence were significant risk factors for lost follow-up.

Conclusions: Long-term follow-up is necessary after RCC surgery because late recurrence cases are not uncommon. We believe that lifelong follow-up with imaging studies is recommended for postoperative RCC patients. Early detection of recurrence in postoperative patients is a very important issue, and it may be worthwhile for improving the prognosis of postoperative patients to focus on patients lost to follow-up who may have been overlooked.

Keywords: Lost follow-up free survival; Nephrectomy; Postoperative; Recurrence; Renal cell carcinoma.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries. CA Cancer J Clin 71(3):209–249. https://doi.org/10.3322/caac.21660 - DOI - PubMed
    1. Marumo K, Kanayama H, Miyao N et al (2007) Prevalence of renal cell carcinoma: a nation-wide survey in Japan, 2002. Int J Urol 14(6):479–482. https://doi.org/10.1111/j.1442-2042.2007.01739.x - DOI - PubMed
    1. Dabestani S, Marconi L, Kuusk T et al (2018) Follow-up after curative treatment of localised renal cell carcinoma. World J Urol 36(12):1953–1959. https://doi.org/10.1007/s00345-018-2338-z - DOI - PubMed
    1. Frees SK, Kamal MM, Nestler S et al (2019) Risk-adjusted proposal for >60 months follow up after surgical treatment of organ-confined renal cell carcinoma according to life expectancy. Int J Urol 26(3):385–390. https://doi.org/10.1111/iju.13882 - DOI - PubMed
    1. Stewart-Merrill SB, Thompson RH, Boorjian SA et al (2015) Oncologic surveillance after surgical resection for renal cell carcinoma: a novel risk-based approach. J Clin Oncol 33(35):4151–4157. https://doi.org/10.1200/jco.2015.61.8009 - DOI - PubMed

Grants and funding

LinkOut - more resources